StockData
Creative Medical Technology Holdings, Inc. logo

Creative Medical Technology Holdings, Inc. (CELZ) stock

CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$0.62−0.01 (-2.08%)

Close on Nov 12, 2026Market cap $4.06MP/E –Yield –

Creative Medical Technology gross margin

Gross margin is gross profit as a percentage of revenue.

Creative Medical Technology's gross margin for the twelve months ending Sep 30, 2026 was 66.9%. For fiscal 2025 it was 63.4%, against 60.0% the year before. The highest annual figure on record is 72.5% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202563.4%+3.4
FY2024Dec 31, 202460.0%+0.0
FY2023Dec 31, 202360.0%−7.8
FY2022Dec 31, 202267.8%+22.5
FY2021Dec 31, 202145.4%−23.9
FY2020Dec 31, 202069.2%−3.3
FY2019Dec 31, 201972.5%+29.1
FY2018Dec 31, 201843.4%+110.1
FY2017Dec 31, 2017-66.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 202566.9%+6.9
Q1 FY2025Mar 31, 202560.0%+0.0
Q4 FY2024Dec 31, 202460.0%−9.4
Q2 FY2024Jun 30, 202460.0%−10.9
Q4 FY2023Dec 31, 202360.0%+5.3
Q3 FY2023Sep 30, 202360.0%+18.2
Q4 FY2022Dec 31, 202269.4%+9.4
Q3 FY2022Sep 30, 202270.9%+15.9
Q1 FY2022Mar 31, 202254.7%+0.4
Q4 FY2021Dec 31, 202141.8%−35.4
Q3 FY2021Sep 30, 202160.0%−1.3
Q2 FY2021Jun 30, 202155.0%−11.3
Q4 FY2020Dec 31, 202054.3%−31.8
Q3 FY2020Sep 30, 202077.1%+8.3
Q2 FY2020Jun 30, 202061.3%−10.7
Q1 FY2020Mar 31, 202066.3%+16.7
Q3 FY2019Sep 30, 201986.1%+55.5
Q2 FY2019Jun 30, 201968.8%+21.5
Q1 FY2019Mar 31, 201972.0%−3.0
Q4 FY2018Dec 31, 201849.6%+116.2
Q3 FY2018Sep 30, 201830.5%–
Q2 FY2018Jun 30, 201847.3%–
Q1 FY2018Mar 31, 201875.0%–
Q4 FY2017Dec 31, 2017-66.7%–

More Creative Medical Technology figures

See a number that looks wrong?